Related Experiment Video
Updated: Jul 1, 2025

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Interruption of p38MAPK-MSK1-CREB-MITF-M pathway to prevent hyperpigmentation in the skin
Song-Hee Kim1, Jiyeon Lee1, Jihye Jung1
1College of Pharmacy, Chungbuk National University, Cheongju 28160, Korea.
Abstract:
Background: Melanocortin 1 receptor (MC1R), a receptor of α-melanocyte-stimulating hormone (α-MSH), is exclusively present in melanocytes where α-MSH/MC1R stimulate melanin pigmentation through microphthalmia-associated transcription factor M (MITF-M). Toll-like receptor 4 (TLR4), a receptor of endotoxin lipopolysaccharide (LPS), is distributed in immune and other cell types including melanocytes where LPS/TLR4 activate transcriptional activity of nuclear factor (NF)-κB to express cytokines in innate immunity. LPS/TLR4 also up-regulate MITF-M-target melanogenic genes in melanocytes. Here, we propose a molecular target of antimelanogenic activity through elucidating inhibitory mechanism on α-MSH-induced melanogenic programs by benzimidazole-2-butanol (BI2B), an inhibitor of LPS/TLR4-activated transcriptional activity of NF-κB. Methods: Ultraviolet B (UV-B)-irradiated skins of HRM-2 hairless mice and α-MSH-activated melanocyte cultures were employed to examine melanogenic programs. Results: Topical treatment with BI2B ameliorated UV-B-irradiated skin hyperpigmentation in mice. BI2B suppressed the protein or mRNA levels of melanogenic markers, such as tyrosinase (TYR), MITF-M and proopiomelanocortin (POMC), in UV-B-exposed and pigmented skin tissues. Moreover, BI2B inhibited melanin pigmentation in UV-B-irradiated co-cultures of keratinocyte and melanocyte cells and that in α-MSH-activated melanocyte cultures. Mechanistically, BI2B inhibited the activation of cAMP response element-binding protein (CREB) in α-MSH-induced melanogenic programs and suppressed the expression of MITF-M at the promoter level. As a molecular target, BI2B primarily inhibited mitogen-activated protein kinase (MAPK) kinase 3 (MKK3)-catalyzed kinase activity on p38MAPK. Subsequently, BI2B interrupted downstream pathway of p38MAPK-mitogen and stress-activated protein kinase-1 (MSK1)-CREB-MITF-M, and suppressed MITF-M-target melanogenic genes, encoding enzymes TYR, TYR-related protein-1 (TRP-1) and dopachrome tautomerase (DCT) in melanin biosynthesis, and encoding proteins PMEL17 and Rab27A in the transfer of pigmented melanosomes to the overlaying keratinocytes in the skin. Conclusion: Targeting the MKK3-p38MAPK-MSK1-CREB-MITF-M pathway was suggested as a rationale to inhibit UV-B- or α-MSH-induced facultative melanogenesis and as a strategy to prevent acquired pigmentary disorders in the skin.
Insights
Benzimidazole-2-butanol (BI2B) inhibits UV-B-induced skin hyperpigmentation by blocking the MKK3-p38MAPK-MSK1-CREB-MITF-M pathway. This compound reduces melanogenesis, offering a strategy for pigmentary disorders.
Area of Science:
- Dermatology
- Molecular Biology
- Pharmacology
Background:
- Melanocortin 1 receptor (MC1R) and Toll-like receptor 4 (TLR4) pathways regulate melanogenesis in skin melanocytes.
- α-melanocyte-stimulating hormone (α-MSH) binding to MC1R stimulates melanin production via MITF-M.
- Lipopolysaccharide (LPS) binding to TLR4 activates NF-κB and upregulates melanogenic genes.
Purpose of the Study:
- To investigate the antimelanogenic activity of benzimidazole-2-butanol (BI2B).
- To elucidate the inhibitory mechanism of BI2B on α-MSH-induced melanogenic programs.
- To explore BI2B as a potential therapeutic strategy for acquired pigmentary disorders.
Main Methods:
- Utilized UV-B irradiated hairless mice and α-MSH-activated melanocyte cultures.
- Assessed melanogenic markers (TYR, MITF-M, POMC) at protein and mRNA levels.
- Investigated the molecular pathway involving MKK3, p38MAPK, MSK1, CREB, and MITF-M.
Main Results:
- BI2B treatment ameliorated UV-B-induced skin hyperpigmentation in mice.
- BI2B suppressed key melanogenic markers and inhibited melanin production in vitro and in vivo.
- BI2B blocked the MKK3-p38MAPK-MSK1-CREB-MITF-M signaling cascade.
Conclusions:
- Targeting the MKK3-p38MAPK-MSK1-CREB-MITF-M pathway is a viable strategy to inhibit melanogenesis.
- BI2B demonstrates potential for preventing and treating acquired pigmentary disorders.
- This study provides a molecular rationale for developing novel antimelanogenic agents.
More Related Videos
Related Concept Videos
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
The JAK-STAT Signaling Pathway
TGF - β Signaling Pathway

